If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Atypical chronic pain syndrome Body dysmorphic disorder (dysmorphic syndrome, dysmorphophobia) Brachioradial pruritus Bromidrosiphobia Complex regional pain syndrome (reflex sympathetic dystrophy) Congenital insensitivity to pain with anhidrosis Delusional parasitosis (delusions of parasitosis, Ekbom syndrome, monosymptomatic hypochondriacal psychosis) Dermatothlasia Dermatitis artefacta (factitious dermatitis, factitial dermatitis) Glossodynia (burning mouth syndrome, burning tongue, orodynia) Levator ani syndrome Malum perforans pedis (neurotrophic ulcer, perforating ulcer of the foot) Meralgia paresthetica (Roth–Bernhardt disease) Neurotic excoriations Notalgia paresthetica (hereditary localized pruritus, posterior pigmented pruritic patch, subscapular pruritus) Postencephalitic trophic ulcer Psychogenic pruritus Riley–Day syndrome (familial dysautonomia) Scalp dysesthesia Sciatic nerve injury Scrotodynia Syringomyelia (Morvan's disease) Traumatic neuroma (amputation neuroma) Trichotillomania (trichotillosis) Trigeminal neuralgia (tic douloureux) Trigeminal trophic lesion (trigeminal trophic syndrome) Vulvodynia (vestibulodynia)
As glucokinase is a monomeric enzyme with only a single binding site for glucose the cooperativity cannot be explained in terms of classical models of equilibrium cooperativity, but requires a kinetic explanation, such as a slow-transition model or a "memonical" model that invokes enzyme memory. The kinetic relationship with the other substrate, MgATP, can be described by classical Michaelis-Menten kinetics, with an affinity at about 0.3–0.4 mM, well below a typical intracellular concentration of 2.5 mM. The fact that there is nearly always an excess of ATP available implies that ATP concentration rarely influences glucokinase activity. The maximum specific activity (kcat) of glucokinase when saturated with both substrates is 62/s. The pH optimum of human glucokinase was identified only recently and is surprisingly high, at pH 8.5–8.7. A "minimal mathematical model" has been devised based on the above kinetic information to predict the beta cell glucose phosphorylation rate (BGPR) of normal ("wild type") glucokinase and the known mutations. The BGPR for wild type glucokinase is about 28% at a glucose concentration of 5 mM, indicating that the enzyme is running at 28% of capacity at the usual threshold glucose for triggering insulin release.
Indeed, the urban areas of the country suffering heavily from unemployment, which might have been expected to respond the most to the radical economic policies of the Liberals, instead gave the party its worst results. By contrast, most of the party's seats were won either due to the absence of a candidate from one of the other parties or in rural areas on the Celtic fringe, where local evidence suggests that economic ideas were at best peripheral to the electorate's concerns. The Liberals now found themselves with 59 members, holding the balance of power in a Parliament where Labour was the largest party but lacked an overall majority. Lloyd George offered a degree of support to the Labour government in the hope of winning concessions, including a degree of electoral reform to introduce the alternative vote, but this support was to prove bitterly divisive as the Liberals increasingly divided between those seeking to gain what Liberal goals they could achieve, those who preferred a Conservative government to a Labour one and vice versa.
Chestnuts can vary widely in shade and different terms are sometimes used to describe these shades, even though they are genetically indistinguishable. Collectively, these coat colors are usually called "red" by geneticists.
Sources: en.wikipedia.org
=== Linear copolymers === Due to the wide variety of copolymers possible, there is no single accepted naming convention, but IUPAC has a general suggested naming scheme that indicates the organization of repeat units within a copolymers. In this convention, source based nomenclature is used to indicate the monomers from which the copolymer was synthesized. Following the IUPAC naming conventions, a generally copolymer is named poly(A-co-B), where A and B are the monomers and -co- represents the type of copolymer. This linkers changes with the type of copolymers, examples of which are shown below. If the exact structure of the polymer is unknown, the linker -co- should be used.
== References == Black, David; Bolton, Geoffrey (2001a). Biographical Register of Members of the Parliament of Western Australia. Vol. One: 1870–1930 (Revised ed.). Parliament House: Parliament of Western Australia. ISBN 0730738140. Hansard Indexes for 1933-1936, "Legislature of Western Australia" "Special (No.19)". Western Australia Government Gazette. 24 April 1933. p. 1933:621. Also 1935:727 (29 March 1935), 1936:684 (13 May 1936), 1936:1113 (23 July 1936) and 1936:1276 (20 August 1936).
=== Promotions === Pre-purchasing of the Windows version on Steam began on September 11, 2007. Those who pre-purchased via this method received a ten-percent discount and were able to play the Team Fortress 2 beta starting on September 17, 2007. The original PC version of The Orange Box came with Peggle Extreme, a ten-level playable demo of Peggle Deluxe, which contained levels with graphical themes of games contained in The Orange Box. However Peggle Extreme was later made free to download for anyone with a Steam account and is not included in the current PC version of the Orange Box on Steam. Half-Life 2: Lost Coast is also technically included with the PC version of The Orange Box, as it was offered as a free download to all owners of Half-Life 2. And as of 2024 is listed as a part of the Orange Box after Lost Coast and Half-Life 2 Episodes One, and Two were integrated into Half-Life 2 as a part of its 20th anniversary update. The same is true for Half-Life 2: Deathmatch, which is now included with Half-Life 2 following Half-Life 2's 20th anniversary update.
=== Automated culturing systems === Automatic cell culturing systems are becoming popular because of their ability to maintain a sterile growth environment and remove strain on the laboratory staff involving repetitive experimentation. Laboratories can also set incubation times to adjust for the lag period involved in bacterial growth.
=== Second stranding === Between January 9 and January 15, a storm tide dragged the carcass out to sea, but it washed ashore again on the next tide, on Crescent Beach, two miles to the south of its original location. Webb sent photographs of the mass, along with a description, to Joel Asaph Allen of the Museum of Comparative Zoology at Harvard. Allen apparently did not respond, but Webb's letter came to the attention of Prof. Addison Emery Verrill of Yale, at that time the foremost authority on cephalopods in the country. At first, Verrill suggested the carcass might represent the remains of a giant squid. In the January 1897 issue of the American Journal of Science he wrote:
Sources: en.wikipedia.org
2-Bromodeschloroketamine (also known as 2-Br-2'-Oxo-PCM and bromoketamine) is a chemical compound of the arylcyclohexylamine class, which is an analog of the dissociative anesthetic drug ketamine in which the chlorine atom has been replaced with a bromine atom. Its specific pharmacological activities have not been studied. It is used in scientific research as a comparison or control compound in studies into the metabolism of ketamine and norketamine. It has been sold online as a designer drug.
It is also used to treat myxedema coma, which is a severe form of hypothyroidism characterized by mental status changes and hypothermia. As it is a medical emergency with a high mortality rate, it should be treated in the intensive-care unit with thyroid hormone replacement and aggressive management of individual organ system complications.
They are said to exert influence both across all domains of experience and throughout the stages of each individual's unique development. Being in part based on heritable physiology, they are thought to have "existed" since humans became a differentiated species. They have been deduced through the development of storytelling over tens of thousands of years, indicating repeating patterns of individual and group experience, behaviours, and effects across the planet, apparently displaying common themes. Jung argued that the different stages of life (childhood, adolescence, adulthood etc.) are mediated through different archetypes.
The four substrates of this enzyme are albendazole, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen and a proton. Its products are ricobendazole (albendazole S-oxide), oxidised NADP+, and water. This enzyme is coded by the gene for FMO3 and is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is albendazole,NADPH:oxygen oxidoreductase (sulfoxide-forming). Other names in common use include albendazole oxidase, and albendazole sulfoxidase. It employs one cofactor, flavin adenine dinucleotide.
Urea, also called carbamide (because it is a diamide of carbonic acid), is an organic compound with chemical formula CO(NH2)2. This amide has two amino groups (−NH2) joined by a carbonyl functional group (−C(=O)−). It is thus the simplest amide of carbamic acid. Urea serves an important role in the cellular metabolism of nitrogen-containing compounds by animals and is the main nitrogen-containing substance in the urine of mammals. The word urea is Neo-Latin, from French urée, from Ancient Greek οὖρον (oûron) 'urine'. It is a colorless, odorless solid, highly soluble in water, and practically non-toxic. Dissolved in water, it is neither acidic nor alkaline. The body uses it in many processes, most notably nitrogen excretion. In the liver, it forms by the condensation of ammonia (NH3) and carbon dioxide (CO2) in the urea cycle. Urea is widely used in fertilizers as a source of nitrogen (N). In 1828, Friedrich Wöhler showed that urea can be produced from inorganic starting materials, an important conceptual milestone in chemistry. This showed for the first time that a substance previously known only as a byproduct of life could be synthesized in the laboratory from non-biological starting materials, thereby contradicting the widely held doctrine of vitalism, which stated that organic compounds could only be derived from living organisms.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.